Option chain shows key data for OS Therapies's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for OS Therapies.

OS Therapies (AMEX:OSTX) Stock, Option Chain

OS Therapies

OS Therapies Inc is a clinical stage biopharmaceutical company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. The companys mission is to address the significant need for new treatments in cancers of the bone in children and young adults.

ostx

Biotech

News

Health Care

Contracts

Movers

Trading Ideas

General

OSTX

OS Therapies advances OST-HER2, a HER2-targeted immunotherapy, with plans for FDA submission following promising Phase 2b data in osteosarcoma.

Small-Cap OS Therapies Inks Commercial Manufacture Agreements For Lead Cancer Drug For Rare Type Of Bone Cancer

cancer

Equities

OS Therapies shares Phase 2b trial results showing OST-HER2 improves survival rates in rare metastatic osteosarcoma, surpassing historical controls.

Why Is Pediatric-Cancer Focused OS Therapies Stock Trading Higher On Wednesday?

movers image

Pre-Market Outlook

Markets

ABLV

ALTS

AMIX

APDN

BFRI

CING

DGLY

FOXA

FUBO

GOVX

MREO

NVOS

QNCX

SPRC

VRAX

VSME

XPER

ZCAR

Why Xperi Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket

OS Therapies Inc

Press Releases

RedChip Launches RedChat: Revolutionary AI Chatbot for Small-Cap Stock Analysis

OS Therapies Provides Corporate Update

OS Therapies Initiates Commercial-ready Manufacturing of OST-HER2 to Support Anticipated Biologics Licensing Authorization (BLA) Filing

OS Therapies Receives Patent Notice of Allowance from U.S. Patent & Trademark Office Covering Commercial Manufacturing of OST-HER2

OS Therapies Forms Subsidiary OS Drug Conjugates and Initiates Review of Strategic Options for its tunable ADC & Drug Conjugates Platforms

Join OS Therapies' Exclusive Live Investor Webinar and Q&A Session on February 27

Spin-Offs: Potential Catalysts for Big Gains

Calidi Biotherapeutics and OS Therapies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

OS Therapies Schedules United Kingdom's Medicines and Healthcare products Regulatory Agency's (MHRA) Scientific Advice Meeting in the Third Quarter of 2025 for Review of its OST-HER2 Immunotherapy Candidate for Osteosarcoma

OS Therapies Awarded OST-HER2 Clinical Trial Data Presentation at MIB Agents FACTOR Osteosarcoma Conference

BFRG

CLDI

CNTM

GRRR

SXTP

Abpro Hldgs

Akari Therapeutics Plc - American Depositary Shares

Akari Therapeutics

Annovis Bio

Celularity

CollPlant Biotechnologies Ltd. - Ordinary Shares

CollPlant Biotechnologies

Chemomab Therapeutics Ltd. - American Depositary Shares

Chemomab Therapeutics

Coeptis Therapeutics Holdings, Inc. - Common Stock

Coeptis Therapeutics

Elevation Oncology

Equillium

Estrella Immunopharma, Inc. - Common Stock

Estrella Immunopharma

FibroBiologics

Forte Biosciences

FibroGen

CytoMed Therapeutics Limited - Ordinary Shares

CytoMed Therapeutics

MiNK Therapeutics

Intensity Therapeutics, Inc. - Common Stock

Intensity Therapeutics

OSR Holdings

Ovid Therapeutics

Passage Bio

Pluri

Rallybio

RenovoRx

Surrozen

Tempest Therapeutics, Inc. - Common Stock

Tempest Therapeutics

Unity Biotechnology

D. Boral Capital

Maxim Group

EF Hutton

Comments

OS Therapies

OS Therapies (OSTX) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga